Inventiva S.A.

3.14
0.12 (3.97%)
At close: Apr 04, 2025, 3:46 PM
3.97%
Bid 3.02
Market Cap 299.83M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -3.32
PE Ratio (ttm) -0.95
Forward PE -1.39
Analyst Buy
Ask 3.29
Volume 73,163
Avg. Volume (20D) 9,642
Open 3.44
Previous Close 3.02
Day's Range 2.90 - 3.46
52-Week Range 1.53 - 3.98
Beta 0.99

About IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype ...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 123
Stock Exchange NASDAQ
Ticker Symbol IVA
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for IVA stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 314.01% from the latest price.

Stock Forecasts
1 month ago
+1.11%
Inventiva shares are trading lower. The company an... Unlock content with Pro Subscription
2 months ago
+3.6%
Inventiva shares are trading higher after the company announced results from the investigator-initiated proof-of-concept clinical trial.